{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T11:15:38Z","timestamp":1788520538296,"version":"build-2803163510"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,5,15]],"date-time":"2025-05-15T00:00:00Z","timestamp":1747267200000},"content-version":"vor","delay-in-days":14,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100012990","name":"Universit\u00e0 degli Studi di Siena","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100012990","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2025,5]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    The glycoprotein CD47 is an innate immune checkpoint ubiquitously expressed on all healthy cells to prevent themselves from phagocytosis. CD47 binds to its receptor SIRP\u03b1 on macrophages, thus producing a signal transduction cascade which inhibits phagocytosis. CD47 is overexpressed on various solid and hematologic malignancies in order to escape the immune system. High expression of CD47 in patients with AML has been associated with poor prognosis, however, there is no standard technique to assess CD47 expression on AML blasts in clinical practice and the real prognostic value of CD47 overexpression varies among studies in the current literature. In this study, CD47 expression was evaluated by flow cytometry on AML blasts from bone marrow samples at diagnosis and reported in terms of median fluorescence intensity (MFI). Flow cytometry analysis demonstrated the expression of CD47 in all AML patients with a median MFI on leukemic blasts of 16.8 (range 2\u2013693.63). CD47 levels on AML blasts correlated with WBC count (rs 0.403,\n                    <jats:italic>p<\/jats:italic>\n                    \u2009=\u20090.016), BM blasts percentage (rs 0.494,\n                    <jats:italic>p<\/jats:italic>\n                    \u2009=\u20090.003), PB blasts percentage (rs 0.482,\n                    <jats:italic>p<\/jats:italic>\n                    \u2009=\u20090.003) and LDH levels (rs 0.382,\n                    <jats:italic>p<\/jats:italic>\n                    \u2009=\u20090.028) and higher expression of CD47 was associated with reduced survival with a hazard ratio of 1.04 (CI: 1.01\u20131.08,\n                    <jats:italic>p<\/jats:italic>\n                    \u2009=\u20090.047). Further studies with larger sample sizes are necessary to better define the real prognostic value of CD47 overexpression in the complexity of AML tumor microenvironment and, possibly, to identify a subgroup of patients who could derive maximum benefit from emerging CD47-SIRP\u03b1 blocking therapies.\n                  <\/jats:p>","DOI":"10.1007\/s00277-025-06401-2","type":"journal-article","created":{"date-parts":[[2025,5,14]],"date-time":"2025-05-14T19:59:00Z","timestamp":1747252740000},"page":"2737-2743","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Prognostic value of CD47 overexpression measured by flow cytometry in acute myeloid leukemia"],"prefix":"10.1007","volume":"104","author":[{"given":"Vincenzo","family":"Sammartano","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Sicuranza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paola","family":"Pacelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Bestoso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adele","family":"Santoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Corrado Zuanelli","family":"Brambilla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marzia","family":"Defina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandra","family":"Cartocci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donatella","family":"Raspadori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monica","family":"Bocchia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,5,15]]},"reference":[{"issue":"3","key":"6401_CR1","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1002\/ajh.26822","volume":"98","author":"S Shimony","year":"2023","unstructured":"Shimony S, Stahl M, Stone RM (2023) Acute myeloid leukemia: 2023 update on diagnosis, risk-stratification, and management. Am J Hematol 98(3):502\u2013526","journal-title":"Am J Hematol"},{"issue":"18","key":"6401_CR2","doi-asserted-by":"publisher","first-page":"4179","DOI":"10.1182\/blood-2008-07-172007","volume":"113","author":"G Juliusson","year":"2009","unstructured":"Juliusson G, Antunovic P, Derolf A, Lehmann S, M\u00f6llg\u00e5rd L, Stockelberg D, Tidefelt U, Wahlin A, H\u00f6glund M (2009) Age and acute myeloid leukemia: real world data on decision to treat and outcomes from the Swedish acute leukemia registry. Blood 113(18):4179\u20134187","journal-title":"Blood"},{"issue":"12","key":"6401_CR3","doi-asserted-by":"publisher","first-page":"2049","DOI":"10.1002\/cncr.33458","volume":"127","author":"K Sasaki","year":"2021","unstructured":"Sasaki K, Ravandi F, Kadia TM, DiNardo CD, Short NJ, Borthakur G, Jabbour E, Kantarjian HM (2021) De Novo acute myeloid leukemia: A population-based study of outcome in the united States based on the surveillance, epidemiology, and end results (SEER) database, 1980 to 2017. Cancer 127(12):2049\u20132061","journal-title":"Cancer"},{"issue":"6","key":"6401_CR4","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1016\/j.blre.2018.04.005","volume":"32","author":"A Russ","year":"2018","unstructured":"Russ A, Hua AB, Montfort WR, Rahman B, Riaz IB, Khalid MU, Carew JS, Nawrocki ST, Persky D, Anwer F (2018) Blocking don\u2019t eat me signal of CD47-SIRP\u03b1 in hematological malignancies, an in-depth review. Blood Rev 32(6):480\u2013489","journal-title":"Blood Rev"},{"key":"6401_CR5","doi-asserted-by":"publisher","first-page":"757480","DOI":"10.3389\/fimmu.2022.757480","volume":"13","author":"H Zhao","year":"2022","unstructured":"Zhao H, Song S, Ma J, Yan Z, Xie H, Feng Y, Che S (2022) CD47 as a promising therapeutic target in oncology. Front Immunol 13:757480","journal-title":"Front Immunol"},{"key":"6401_CR6","doi-asserted-by":"publisher","first-page":"1265299","DOI":"10.3389\/fimmu.2023.1265299","volume":"14","author":"H Cao","year":"2023","unstructured":"Cao H, Wu T, Zhou X, Xie S, Sun H, Sun Y, Li Y (2023) Progress of research on PD-1\/PD-L1 in leukemia. Front Immunol 14:1265299","journal-title":"Front Immunol"},{"issue":"1","key":"6401_CR7","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1186\/s13045-020-00930-1","volume":"13","author":"E Eladl","year":"2020","unstructured":"Eladl E, Tremblay-LeMay R, Rastgoo N, Musani R, Chen W, Liu A, Chang H (2020) Role of CD47 in hematological malignancies. J Hematol Oncol 13(1):96","journal-title":"J Hematol Oncol"},{"issue":"2","key":"6401_CR8","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1016\/j.cell.2009.05.046","volume":"138","author":"S Jaiswal","year":"2009","unstructured":"Jaiswal S, Jamieson CH, Pang WW, Park CY, Chao MP, Majeti R, Traver D, van Rooijen N, Weissman IL (2009) CD47 is upregulated on Circulating hematopoietic stem cells and leukemia cells to avoid phagocytosis. Cell 138(2):271\u2013285","journal-title":"Cell"},{"issue":"2","key":"6401_CR9","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1016\/j.cell.2009.05.045","volume":"138","author":"R Majeti","year":"2009","unstructured":"Majeti R, Chao MP, Alizadeh AA, Pang WW, Jaiswal S, Gibbs KD Jr, van Rooijen N, Weissman IL (2009) CD47 is an adverse prognostic factor and therapeutic antibody target on human acute myeloid leukemia stem cells. Cell 138(2):286\u2013299","journal-title":"Cell"},{"issue":"7","key":"6401_CR10","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1016\/j.leukres.2015.04.007","volume":"39","author":"S Galli","year":"2015","unstructured":"Galli S, Zlobec I, Sch\u00fcrch C, Perren A, Ochsenbein AF, Banz Y (2015) CD47 protein expression in acute myeloid leukemia: A tissue microarray-based analysis. Leuk Res 39(7):749\u2013756","journal-title":"Leuk Res"},{"issue":"12","key":"6401_CR11","doi-asserted-by":"publisher","first-page":"3491","DOI":"10.3324\/haematol.2023.283154","volume":"108","author":"A Marra","year":"2023","unstructured":"Marra A, Akarca AU, Martino G, Ramsay A, Ascani S, Perriello VM, O\u2019Nions J, Wilson AJ, Gupta R, Childerhouse A, Proctor I, Rodriguez-Justo M, Pomplun S, Martelli MP, Lo Celso C, Falini B, Marafioti T (2023) CD47 expression in acute myeloid leukemia varies according to genotype. Haematologica 108(12):3491\u20133495","journal-title":"Haematologica"},{"issue":"1","key":"6401_CR12","first-page":"81","volume":"56","author":"K Tanaka","year":"2024","unstructured":"Tanaka K, Miyoshi H, Kawamoto K, Shimasaki Y, Nakashima K, Imamoto T, Yamada K, Takeuchi M, Moritsubo M, Furuta T, Kohno K, Tamura S, Sonoki T, Ohshima K (2024) Clinicopathological analysis of CD47 and signal regulatory protein alpha expression in myeloid sarcoma patients: CD47 expression is a favourable prognostic factor. Pathology 56(1):81\u201391","journal-title":"Pathology"},{"key":"6401_CR13","doi-asserted-by":"publisher","first-page":"1380","DOI":"10.3389\/fonc.2019.01380","volume":"9","author":"MP Chao","year":"2020","unstructured":"Chao MP, Takimoto CH, Feng DD, McKenna K, Gip P, Liu J, Volkmer JP, Weissman IL, Majeti R (2020) Therapeutic targeting of the macrophage immune checkpoint CD47 in myeloid malignancies. Front Oncol 9:1380","journal-title":"Front Oncol"},{"key":"6401_CR14","doi-asserted-by":"publisher","first-page":"1378647","DOI":"10.3389\/fonc.2024.1378647","volume":"14","author":"C Jiang","year":"2024","unstructured":"Jiang C, Sun H, Jiang Z, Tian W, Cang S, Yu J (2024) Targeting the CD47\/SIRP\u03b1 pathway in malignancies: recent progress, difficulties and future perspectives. Front Oncol 14:1378647","journal-title":"Front Oncol"},{"issue":"11","key":"6401_CR15","doi-asserted-by":"publisher","first-page":"1200","DOI":"10.1182\/blood.2022015850","volume":"140","author":"DA Arber","year":"2022","unstructured":"Arber DA, Orazi A, Hasserjian RP, Borowitz MJ, Calvo KR, Kvasnicka HM, Wang SA, Bagg A, Barbui T, Branford S, Bueso-Ramos CE, Cortes JE, Dal Cin P, DiNardo CD, Dombret H, Duncavage EJ, Ebert BL, Estey EH, Facchetti F, Foucar K, Gangat N, Gianelli U, Godley LA, G\u00f6kbuget N, Gotlib J, Hellstr\u00f6m-Lindberg E, Hobbs GS, Hoffman R, Jabbour EJ, Kiladjian JJ, Larson RA, Le Beau MM, Loh ML, L\u00f6wenberg B, Macintyre E, Malcovati L, Mullighan CG, Niemeyer C, Odenike OM, Ogawa S, Orfao A, Papaemmanuil E, Passamonti F, Porkka K, Pui CH, Radich JP, Reiter A, Rozman M, Rudelius M, Savona MR, Schiffer CA, Schmitt-Graeff A, Shimamura A, Sierra J, Stock WA, Stone RM, Tallman MS, Thiele J, Tien HF, Tzankov A, Vannucchi AM, Vyas P, Wei AH, Weinberg OK, Wierzbowska A, Cazzola M, D\u00f6hner H, Tefferi A (2022) International consensus classification of myeloid neoplasms and acute leukemias: integrating morphologic, clinical, and genomic data. Blood 140(11):1200\u20131228","journal-title":"Blood"},{"key":"6401_CR16","doi-asserted-by":"crossref","unstructured":"Khoury JD, Solary E, Abla O, Akkari Y, Alaggio R, Apperley JF, Bejar R, Berti E, Busque L, Chan JKC, Chen W, Chen X, Chng WJ, Choi JK, Colmenero I, Coupland SE, Cross NCP, De Jong D, Elghetany MT, Takahashi E, Emile JF, Ferry J, Fogelstrand L, Fontenay M, Germing U, Gujral S, Haferlach T, Harrison C, Hodge JC, Hu S, Jansen JH, Kanagal-Shamanna R, Kantarjian HM, Kratz CP, Li XQ, Lim MS, Loeb K, Loghavi S, Marcogliese A, Meshinchi S, Michaels P, Naresh KN, Natkunam Y, Nejati R, Ott G, Padron E, Patel KP, Patkar N, Picarsic J, Platzbecker U, Roberts I, Schuh A, Sewell W, Siebert R, Tembhare P, Tyner J, Verstovsek S, Wang W, Wood B, Xiao W, Yeung C, Hochhaus A (2022) The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic\/Dendritic Neoplasms. Leukemia 36(7):1703\u20131719","DOI":"10.1038\/s41375-022-01613-1"},{"issue":"12","key":"6401_CR17","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1182\/blood.2022016867","volume":"140","author":"H D\u00f6hner","year":"2022","unstructured":"D\u00f6hner H, Wei AH, Appelbaum FR, Craddock C, DiNardo CD, Dombret H, Ebert BL, Fenaux P, Godley LA, Hasserjian RP, Larson RA, Levine RL, Miyazaki Y, Niederwieser D, Ossenkoppele G, R\u00f6llig C, Sierra J, Stein EM, Tallman MS, Tien HF, Wang J, Wierzbowska A, L\u00f6wenberg B (2022) Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN. Blood 140(12):1345\u20131377","journal-title":"Blood"},{"issue":"13","key":"6401_CR18","doi-asserted-by":"publisher","first-page":"3281","DOI":"10.7150\/ijbs.60782","volume":"17","author":"X Jia","year":"2021","unstructured":"Jia X, Yan B, Tian X, Liu Q, Jin J, Shi J, Hou Y (2021) CD47\/SIRP\u03b1 pathway mediates cancer immune escape and immunotherapy. Int J Biol Sci 17(13):3281\u20133287","journal-title":"Int J Biol Sci"},{"issue":"9","key":"6401_CR19","doi-asserted-by":"publisher","first-page":"1364","DOI":"10.1200\/JCO.1987.5.9.1364","volume":"5","author":"JP Dutcher","year":"1987","unstructured":"Dutcher JP, Schiffer CA, Wiernik PH (1987) Hyperleukocytosis in adult acute nonlymphocytic leukemia: impact on remission rate and duration, and survival. J Clin Oncol 5(9):1364\u20131372","journal-title":"J Clin Oncol"},{"issue":"16","key":"6401_CR20","doi-asserted-by":"publisher","first-page":"R921","DOI":"10.1016\/j.cub.2020.06.081","volume":"30","author":"NM Anderson","year":"2020","unstructured":"Anderson NM, Simon MC (2020) The tumor microenvironment. Curr Biol 30(16):R921\u2013R925","journal-title":"Curr Biol"},{"issue":"14","key":"6401_CR21","doi-asserted-by":"publisher","first-page":"3597","DOI":"10.3390\/cancers13143597","volume":"13","author":"E Cencini","year":"2021","unstructured":"Cencini E, Fabbri A, Sicuranza A, Gozzetti A, Bocchia M (2021) The role of Tumor-Associated macrophages in hematologic malignancies. Cancers (Basel) 13(14):3597","journal-title":"Cancers (Basel)"},{"issue":"10","key":"6401_CR22","doi-asserted-by":"publisher","first-page":"1216","DOI":"10.3324\/haematol.2016.143180","volume":"101","author":"YS Al-Matary","year":"2016","unstructured":"Al-Matary YS, Botezatu L, Opalka B, H\u00f6nes JM, Lams RF, Thivakaran A, Sch\u00fctte J, K\u00f6ster R, Lennartz K, Schroeder T, Haas R, D\u00fchrsen U, Khandanpour C (2016) Acute myeloid leukemia cells polarize macrophages towards a leukemia supporting state in a growth factor independence 1 dependent manner. Haematologica 101(10):1216\u20131227","journal-title":"Haematologica"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-025-06401-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-025-06401-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-025-06401-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,5]],"date-time":"2025-06-05T02:37:54Z","timestamp":1749091074000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-025-06401-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5]]},"references-count":22,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,5]]}},"alternative-id":["6401"],"URL":"https:\/\/doi.org\/10.1007\/s00277-025-06401-2","relation":{},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"value":"0939-5555","type":"print"},{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5]]},"assertion":[{"value":"15 May 2025","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable. The study was conducted in accordance with the ethical standards as laid down in the 1964 Declaration of Helsinki and its later amendments or comparable ethical standards. Patients gave written consent for this study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human ethics and consent to participate"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"The authors report no conflicts of interest.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}